Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease
The neuropathological and clinical symptoms of Huntington's disease (HD) can be simulated in animal model with systemic administration of 3-nitropropionic acid (3-NP). Energy defects in HD could be ameliorated by administration of coenzyme Q10 (CoQ10), creatine, or nicotinamid. We studied the activity of creatine kinase (CK) and the function of mitochondrial respiratory chain in the brain of aged rats administered with 3-NP with and without previous application of antioxidants CoQ10 + vitamin E. We used dynamic and steady-state methods of in vivo phosphorus magnetic resonance spectroscopy (31P MRS) for determination of the pseudo-first order rate constant (kfor) of the forward CK reaction, the phosphocreatine (PCr) to adenosinetriphosphate (ATP) ratio, intracellular pHi and Mgi 2+ content in the brain. The respiratory chain function of isolated mitochondria was assessed polarographically; the concentration of CoQ10 and α-tocopherol by HPLC. We found significant elevation of kfor in brains of 3-NP rats, reflecting increased rate of CK reaction in cytosol. The function of respiratory chain in the presence of succinate was severely diminished. The activity of cytochromeoxidase and mitochondrial concentration of CoQ 10 was unaltered; tissue content of CoQ10 was decreased in 3-NP rats. Antioxidants CoQ10 + vitamin E prevented increase of kfor and the decrease of CoQ10 content in brain tissue, but were ineffective to prevent the decline of respiratory chain function. We suppose that increased activity of CK system could be compensatory to decreased mitochondrial ATP production, and CoQ10 + vitamin E could prevent the increase of kfor after 3-NP treatment likely by activity of CoQ 10 outside the mitochondria. Results of our experiments contributed to elucidation of mechanism of beneficial effect of CoQ10 administration in HD and showed that the rate constant of CK is a sensitive indicator of brain energy disorder reflecting therapeutic effect of drugs that could be used as a new in vivo biomarker of neurodegenerative diseases. © 2005 Elsevier Ltd. All rights reserved.
Record created on 2012-05-26, modified on 2016-08-09